为了参加周选股赛，注意到：2014 FDA Drug Approval Decision Calendar
从中选了短期有活力的三个：AUXL, GSK, ANAC。结果ANAC表现异常好，一不留神整个第一。再挖挖，里面还有宝。
Gilead Sciences
Sofo*****uvir for hepatitis C
Dec. 6
Auxilium Pharmaceuticals
Dec. 6
GlaxoSmithKline
Anoro Ellipta for COPD
Dec. 18
Amarin
Vascepa for mixed dyslipidemia
Dec. 20
Bristol-Myers Squibb
Metreleptin for lipodystrophy
Dec. 11
Bristol-Myers Squibb
Dapagliflozin for Type 2 diabetes
Dec. 12
Biogen Idec
Alprolix for hemophilia B
Jan. 3
Bristol-Myers Squibb
Dapagliflozin for Type 2 diabetes
Jan. 14
Pozen
PA32540 & PA8140 for heart disease
Jan. 24
Vanda Pharmaceuticals
Hetlioz for non-24 sleep disorder
Jan. 31
Chelsea Therapeutics
Northera for orthostatic hypotension
Jan. 14
Alimera Sciences
Iluvien for diabetic macular edema
Jan. 27
Chelsea Therapeutics
Northera for orthostatic hypotension
Feb. 14
United Therapeutics
Oral Remodulin for pulmonary arterial hypertension
Feb. 14
Bristol-Myers Squibb
Metreleptin for lipodystrophy
Feb. 27
Biomarin
Vimizim for morquio syndrome
Feb. 28
Pharmacyclics
Imbruvica for chronic lymphocytic leukemia
Feb. 28
Celgene
Apremilast for psoriatic arthritis
March 21
MannKind
Afrezza for Type 1 and 2 diabetes
April 15
GlaxoSmithKline
Abiglutide for diabetes
April 15
Santarus
Ruconest for hereditary angioedema
April 16
Click ahead for more FDA drug approval decision dates
(GILD_)
(AUXL_)Xiaflex for Peyronie's disease
(GSK_) and Theravance (THRX_)
(AMRN_)
FDA advisory panels:
(BMY_)
January 2014: Drug approval decisions
(BIIB_)
(POZN_)
(VNDA_)
FDA advisory panels:
(CHTP_)
(ALIM_) and pSivida (PSDV_)
February 2014: Drug approval decisions
(UTHR_)
(BMRN_)
(PCYC_) and Johnson & Johnson (JNJ_)
March 2014: Drug approval decisions
(CELG_)
April 2014: Drug approval decisions
(MNKD_)
(GSK)
(SNTS_)
AstraZeneca (AZN_)
(DRTX_)
June 2014: Drug approval decisions
(OMER_)
(LLY_)
(BDSI_)
(KERX_)
(CBST_)
July 2014: Drug approval decisions
(ANAC_)
September 2014: Drug approval decisions
(NKTR_)
October 2014: Drug approval decisions
(NPSP_)
Epanova for hypercholesterolemia
May 5
Gilead Sciences
Idelalisib for indolent non-Hodgkin's lymphoma
May 11 (pending FDA acceptance of priority review)
Biogen Idec
Plegridy for multiple sclerosis
May 21
Durata Therapeutics
Dalbavancin for skin infections
May 26
Omeros
OMS302 for ocular inflammation
June 1
Eli Lilly
Ramucirumab for gastric cancer
June 3
BioDelivery Sciences
Bunavail for opioid addiction
June 7
Keryx Pharmaceuticals
Zerenex for hyperphosphatemia (kidney dialysis)
June 7
Biogen Idec
Eloctate for hemophilia A
June 12
Cubist Pharma
Tedizolid for skin infections
June 22 (pending FDA acceptance of priority review)
Anacor Pharma
Tavaborole for toe fungus
July 29
AstraZeneca and Nektar Therapeutics
Naloxegol for opioid-induced constipation
Sept. 16
NPS Pharmaceuticals
Natpara for hypoparathyroidism
Oct. 24
